Background. Nonalcoholic fatty liver disease is now acknowledged as a complex public health issue linked to sedentary lifestyle, obesity, and related disorders like type 2 diabetes and metabolic syndrome. Aims. We aimed to retrieve its trends out of the huge amount of published data. Therefore, we conducted an extensive literature search to identify possible biomarker and/or biomarker combinations by retrospectively assessing and evaluating common and novel biomarkers to predict progression and prognosis of obesity related liver diseases. Methodology. We analyzed finally 62 articles accounting for 157 cohorts and 45,288 subjects. Results. Despite the various approaches, most cohorts were considerably small and rarely comparable. Also, we found that the same standard parameters were measured rather than novel biomarkers. Diagnostics approaches appeared incomparable. Conclusions. Further collaborative investigations on harmonizing ways of data acquisition and identifying such biomarkers for clinical use are necessary to yield sufficient significant results of potential biomarkers. 1. Introduction Nonalcoholic fatty liver disease (NAFLD) is acknowledged as a (public) health issue with an estimated prevalence of 30% in adults [1], of which approximately 25% progresses to nonalcoholic steatohepatitis (NASH) [2]. Sedentary lifestyle and high-fat and high-caloric dietary intake are strongly associated with NAFLD and nonalcoholic steatohepatitis (NASH). NAFLD and NASH occur not only in adults but also increasingly in childhood [3–5], accounting for a tremendous economic health burden [6]. The pathways of NAFLD/NASH and their alcohol-induced counterpart diseases are multifactorial, involving the liver metabolism key players: cytokines, adipokines, and apoptosis [7]. Alternative tools such as ultrasound or magnetic resonance imaging (MRI) [8] are becoming common in clinical routine; anyway in NAFLD/NASH diagnostics liver biopsy still remains the golden standard [9, 10]. In the context of personalized medicine, the research on biomarker to identify NAFLD and its development and progression is high priority for clinical routine. Our systematic data analysis of NAFLD research conducted in the last year, based on evaluation of extensive literature search, provided an overview of the most commonly published potential biomarkers for NAFLD. 2. Methodology We performed an extensive literature assessment to evaluate known and novel biomarkers for progression and prognosis of NASH/NAFLD. In this context, we extracted and evaluated cohorts and parameters and consolidated
References
[1]
J. D. Browning, L. S. Szczepaniak, R. Dobbins et al., “Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity,” Hepatology, vol. 40, no. 6, pp. 1387–1395, 2004.
[2]
L. A. Adams and K. D. Lindor, “Nonalcoholic fatty liver disease,” Annals of Epidemiology, vol. 17, no. 11, pp. 863–869, 2007.
[3]
E. Poggiogalle, G. Olivero, C. Anania, F. Ferraro, and L. Pacifico, “Pediatric non-alcoholic fatty liver disease: recent advances and challenges,” Minerva Pediatrica, vol. 62, no. 6, pp. 569–584, 2010.
[4]
H. M. Patton, C. Sirlin, C. Behling, M. Middleton, J. B. Schwimmer, and J. E. Lavine, “Pediatric nonalcoholic fatty liver disease: a critical appraisal of current data and implications for future research,” Journal of Pediatric Gastroenterology and Nutrition, vol. 43, no. 4, pp. 413–427, 2006.
[5]
S. E. Mahady, A. C. Webster, S. Walker, A. Sanyal, and J. George, “The role of thiazolidinediones in non-alcoholic steatohepatitis—a systematic review and meta analysis,” Journal of Hepatology, vol. 55, no. 6, pp. 1383–1390, 2011.
[6]
K. S. Bramlage, V. Bansal, S. A. Xanthakos, and R. Kohli, “Fatty liver disease in children—what should one do?” The Indian Journal of Pediatrics, vol. 80, no. 1, pp. 109–114, 2013.
[7]
A. P. Levene and R. D. Goldin, “The epidemiology, pathogenesis and histopathology of fatty liver disease,” Histopathology, vol. 61, no. 2, pp. 141–152, 2012.
[8]
T. Hatta, Y. Fujinaga, M. Kadoya et al., “Accurate and simple method for quantification of hepatic fat content using magnetic resonance imaging: a prospective study in biopsy-proven nonalcoholic fatty liver disease,” Journal of Gastroenterology, vol. 45, no. 12, pp. 1263–1271, 2010.
[9]
Y. Sumida, Y. Eguchi, and M. Ono, “Current status and agenda in the diagnosis of nonalcoholic steatohepatitis in Japan,” World Journal of Hepatology, vol. 2, no. 10, pp. 374–383, 2010.
[10]
V. Ratziu, L. Martin, L. Fedchuk, and T. Poynard, “Can nonalcoholic steatohepatitis be diagnosed without liver biopsy?” Biomarkers in Medicine, vol. 3, no. 4, pp. 353–361, 2009.
[11]
J. W. Tukey, Exploratory Data Analysis, Addison-Wesley Publishing Company, 1977.
[12]
C. Fierbinteanu-Braticevici, C. Baicus, L. Tribus, and R. Papacocea, “Predictive factors for nonalcoholic steatohepatitis (NASH) in patients with nonalcoholic fatty liver disease (NAFLD),” Journal of Gastrointestinal and Liver Diseases, vol. 20, no. 2, pp. 153–159, 2011.
[13]
R. Aller, D. A. de Luis, O. Izaola et al., “G308A polymorphism of TNF-alpha gene is associated with insulin resistance and histological changes in non alcoholic fatty liver disease patients,” Annals of Hepatology, vol. 9, no. 4, pp. 439–444, 2010.
[14]
G. Firneisz, T. Varga, G. Lengyel et al., “Serum dipeptidyl peptidase-4 activity in insulin resistant patients with non-alcoholic fatty liver disease: a novel liver disease biomarker,” PLoS ONE, vol. 5, no. 8, Article ID e12226, 2010.
[15]
C. García-Monzón, O. L. Iacono, R. Mayoral et al., “Hepatic insulin resistance is associated with increased apoptosis and fibrogenesis in nonalcoholic steatohepatitis and chronic hepatitis C,” Journal of Hepatology, vol. 54, no. 1, pp. 142–152, 2011.
[16]
E. Aigner, M. Strasser, H. Haufe et al., “A role for low hepatic copper concentrations in nonalcoholic fatty liver disease,” American Journal of Gastroenterology, vol. 105, no. 9, pp. 1978–1985, 2010.
[17]
C. S？derberg, J. Marmur, K. Eckes et al., “Microvesicular fat, inter cellular adhesion molecule-1 and regulatory T-lymphocytes are of importance for the inflammatory process in livers with non-alcoholic steatohepatitis,” Acta Pathologica, Microbiologica et Immunologica Scandinavica, vol. 119, no. 7, pp. 412–420, 2011.
[18]
A. L. Harte, N. F. Da Silva, S. J. Creely et al., “Elevated endotoxin levels in non-alcoholic fatty liver disease,” Journal of Inflammation, vol. 7, article 15, 2010.
[19]
G. Kilciler, H. Genc, S. Tapan et al., “Mean platelet volume and its relationship with carotid atherosclerosis in subjects with non-alcoholic fatty liver disease,” Upsala Journal of Medical Sciences, vol. 115, no. 4, pp. 253–259, 2010.
[20]
J. Raszeja-Wyszomirska, B. Szymanik, M. ？awniczak et al., “Validation of the BARD scoring system in Polish patients with nonalcoholic fatty liver disease (NAFLD),” BMC Gastroenterology, vol. 10, article 67, 2010.
[21]
D. A. De Luis, R. Aller, O. Izaola, M. G. Sagrado, and R. Conde, “Effect of two different hypocaloric diets in transaminases and insulin resistance in nonalcoholic fatty liver disease and obese patients,” Nutricion Hospitalaria, vol. 25, no. 5, pp. 730–735, 2010.
[22]
P. Manousou, G. Kalambokis, F. Grillo et al., “Serum ferritin is a discriminant marker for both fibrosis and inflammation in histologically proven non-alcoholic fatty liver disease patients,” Liver International, vol. 31, no. 5, pp. 730–739, 2011.
[23]
B. A. Neuschwander-Tetri, J. M. Clark, N. M. Bass et al., “Clinical, laboratory and histological associations in adults with nonalcoholic fatty liver disease,” Hepatology, vol. 52, no. 3, pp. 913–924, 2010.
[24]
M. F. Abdelmalek, A. Suzuki, C. Guy et al., “Increased fructose consumption is associated with fibrosis severity in patients with nonalcoholic fatty liver disease,” Hepatology, vol. 51, no. 6, pp. 1961–1971, 2010.
[25]
C. Xu, L. Xu, C. Yu, M. Miao, and Y. Li, “Association between thyroid function and nonalcoholic fatty liver disease in euthyroid elderly Chinese,” Clinical Endocrinology, vol. 75, no. 2, pp. 240–246, 2011.
[26]
M. Thiruvagounder, S. Khan, and D. S. Sheriff, “Non-alcoholic fatty liver disease (NAFLD)—is it an emerging risk factor for coronary artery disease? Preliminary study in a local Indian population,” Sultan Qaboos University Medical Journal, vol. 10, no. 2, pp. 221–226, 2010.
[27]
Y. Arase, F. Suzuki, M. Kobayashi et al., “The development of chronic kidney disease in Japanese patients with non-alcoholic fatty liver disease,” Internal Medicine, vol. 50, no. 10, pp. 1081–1087, 2011.
[28]
I.-C. Hwang, S.-Y. Suh, A.-R. Suh, and H.-Y. Ahn, “The relationship between normal serum uric acid and nonalcoholic fatty liver disease,” Journal of Korean Medical Science, vol. 26, no. 3, pp. 386–391, 2011.
[29]
C. Xu, C. Yu, L. Xu, M. Miao, and Y. Li, “High serum uric acid increases the risk for nonalcoholic fatty liver disease: a prospective observational study,” PLoS ONE, vol. 5, no. 7, Article ID e11578, 2010.
[30]
J. W. Lee, Y. K. Cho, M. C. Ryan et al., “Serum uric acid as a predictor for the development of nonalcoholic fatty liver disease in apparently healthy subjects: a 5-year retrospective cohort study,” Gut and Liver, vol. 4, no. 3, pp. 378–383, 2010.
[31]
L. Thomas, Laboratory and Diagnosis. Indication and Evaluation/Assessment of Lab Results For Clinical Diagnosticsedition, Frankfurt/Main:TH-Books Publishing Company, 6th edition, 2005.
[32]
A. S. Cardoso, N. C. Gonzaga, C. C. M. Medeiros, and D. F. de Carvalho, “Association of uric acid levels with components of metabolic syndrome and non-alcoholic fatty liver disease in overweight or obese children and adolescents,” Journal De Pediatria, vol. 89, no. 4, pp. 412–418, 2013.
[33]
C. Xu, C. Yu, H. Ma, L. Xu, M. Miao, and Y. Li, “Prevalence and risk factors for the development of nonalcoholic fatty liver disease in a nonobese Chinese population: the Zhejiang Zhenhai study,” The Amercian Journal of Gastroenterology, vol. 108, no. 8, pp. 1299–1304, 2013.
[34]
S. S. Moon, “Relationship between serum uric acid level and nonalcoholic fatty liver disease in pre- and postmenopausal women,” Annals of Nutrition and Metabolism, vol. 62, no. 2, pp. 158–163, 2013.
[35]
K. V. Kowdley, P. Belt, L. A. Wilson et al., “Serum ferritin is an independent predictor of histologic severity and advanced fibrosis in patients with nonalcoholic fatty liver disease,” Hepatology, vol. 55, no. 1, pp. 77–85, 2012.
[36]
L. Valenti, P. Dongiovanni, and S. Fargion, “Diagnostic and therapeutic implications of the association between ferritin level and severity of nonalcoholic fatty liver disease,” World Journal of Gastroenterology, vol. 18, no. 29, pp. 3782–3786, 2012.
[37]
Y. S. Kim, E. S. Jung, W. Hur et al., “Noninvasive predictors of nonalcoholic steatohepatitis in Korean patients with histologically proven nonalcoholic fatty liver disease,” Clinical and Molecular Hepatology, vol. 19, no. 2, pp. 120–130, 2013.
[38]
Y. Yilmaz, O. Yonal, R. Kurt et al., “Serum fetuin A/α2HS-glycoprotein levels in patients with non-alcoholic fatty liver disease: Relation with liver fibrosis,” Annals of Clinical Biochemistry, vol. 47, no. 6, pp. 549–553, 2010.
[39]
A. Kahraman, J. P. Sowa, M. Schlattjan et al., “Fetuin-A mRNA expression is elevated in NASH compared with NAFL patients,” Clinical Science, vol. 125, no. 8, pp. 391–400, 2013.
[40]
B. M. Attar and D. H. Van Thiel, “Current concepts and management approaches in nonalcoholic fatty liver disease,” The Scientific World Journal, vol. 2013, Article ID 481893, 10 pages, 2013.
[41]
S. C. Kalhan, L. Guo, J. Edmison et al., “Plasma metabolomic profile in nonalcoholic fatty liver disease,” Metabolism: Clinical and Experimental, vol. 60, no. 3, pp. 404–413, 2011.
[42]
K. Suzuki, H. Kirikoshi, M. Yoneda et al., “Measurement of spleen volume is useful for distinguishing between simple steatosis and early-stage non-alcoholic steatohepatitis,” Hepatology Research, vol. 40, no. 7, pp. 693–700, 2010.
[43]
H. Rodriguez-Hernandez, M. Cervantes-Huerta, J. L. Gonzalez, M. D. Marquez-Ramirez, M. Rodriguez-Moran, and F. Guerrero-Romero, “Nonalcoholic fatty liver disease in asymptomatic obese women,” Annals of Hepatology, vol. 9, no. 2, pp. 144–149, 2010.
[44]
S. Sookoian, G. O. Casta？o, A. L. Burgue？o, T. F. Gianotti, M. S. Rosselli, and C. J. Pirola, “The nuclear receptor PXR gene variants are associated with liver injury in nonalcoholic fatty liver disease,” Pharmacogenetics and Genomics, vol. 20, no. 1, pp. 1–8, 2010.
[45]
S. Tapan, T. Dogru, M. Kara et al., “Circulating levels of interleukin-18 in patients with non-alcoholic fatty liver disease,” Scandinavian Journal of Clinical and Laboratory Investigation, vol. 70, no. 6, pp. 399–403, 2010.
[46]
K. Hotta, M. Yoneda, H. Hyogo et al., “Association of the rs738409 polymorphism in PNPLA3 with liver damage and the development of nonalcoholic fatty liver disease,” BMC Medical Genetics, vol. 11, no. 1, article 172, 2010.
[47]
S. Sookoian, G. O. Casta？o, A. L. Burgue？o et al., “Circulating levels and hepatic expression of molecular mediators of atherosclerosis in nonalcoholic fatty liver disease,” Atherosclerosis, vol. 209, no. 2, pp. 585–591, 2010.
[48]
C. D. Williams, J. Stengel, M. I. Asike et al., “Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study,” Gastroenterology, vol. 140, no. 1, pp. 124–131, 2011.
[49]
A. Ulitsky, A. N. Ananthakrishnan, R. Komorowski et al., “A noninvasive clinical scoring model predicts risk of nonalcoholic steatohepatitis in morbidly obese patients,” Obesity Surgery, vol. 20, no. 6, pp. 685–691, 2010.
[50]
Y. Eguchi, T. Mizuta, Y. Sumida et al., “The pathological role of visceral fat accumulation in steatosis, inflammation, and progression of nonalcoholic fatty liver disease,” Journal of Gastroenterology, vol. 46, no. 1, pp. 70–78, 2011.
[51]
Y. Sumida, M. Yoneda, H. Hyogo et al., “A simple clinical scoring system using ferritin, fasting insulin, and type IV collagen 7S for predicting steatohepatitis in nonalcoholic fatty liver disease,” Journal of Gastroenterology, vol. 46, no. 2, pp. 257–268, 2011.
[52]
G. Targher, I. Pichiri, G. Zoppini, M. Trombetta, and E. Bonora, “Increased prevalence of chronic kidney disease in patients with Type 1 diabetes and non-alcoholic fatty liver,” Diabetic Medicine, vol. 29, no. 2, pp. 220–226, 2012.
[53]
J. L. Narciso-Schiavon, L. L. de Schiavon, R. J. de Carvalho-Filho et al., “Clinical characteristics associated with hepatic steatosis on ultrasonography in patients with elevated alanine aminotransferase,” Sao Paulo Medical Journal, vol. 128, no. 6, pp. 342–347, 2010.
[54]
H. J. Oh, T. H. Kim, Y. W. Sohn et al., “Association of serum alanine aminotransferase and γ-glutamyltransferase levels within the reference range with metabolic syndrome and nonalcoholic fatty liver disease,” The Korean journal of hepatology, vol. 17, no. 1, pp. 27–36, 2011.
[55]
Z. M. Younossi, S. Page, N. Rafiq et al., “A biomarker panel for non-alcoholic steatohepatitis (NASH) and NASH-Related fibrosis,” Obesity Surgery, vol. 21, no. 4, pp. 431–439, 2011.
[56]
P. Dongiovanni, R. Rametta, A. L. Fracanzani et al., “Lack of association between peroxisome proliferator-activated receptors alpha and gamma2 polymorphisms and progressive liver damage in patients with non-alcoholic fatty liver disease: a case control study,” BMC Gastroenterology, vol. 10, article 102, 2010.
[57]
L. A. Adams, S. Harmsen, J. L. St. Sauver et al., “Nonalcoholic fatty liver disease increases risk of death among patients with diabetes: a community-based cohort study,” American Journal of Gastroenterology, vol. 105, no. 7, pp. 1567–1573, 2010.
[58]
K. Qureshi, R. H. Clements, F. Saeed, and G. A. Abrams, “Comparative evaluation of whole body and hepatic insulin resistance using indices from oral glucose tolerance test in morbidly obese subjects with nonalcoholic fatty liver disease,” Journal of Obesity, vol. 2010, Article ID 741521, 7 pages, 2010.
[59]
S. H. Lee, S.-H. Jeong, Y. S. Park et al., “Serum prohepcidin levels in chronic hepatitis C, alcoholic liver disease, and nonalcoholic fatty liver disease,” The Korean journal of hepatology, vol. 16, no. 3, pp. 288–294, 2010.
[60]
G. Kirovski, D. Schacherer, H. Wobser et al., “Prevalence of ultrasound-diagnosed non-alcoholic fatty liver disease in a hospital cohort and its association with anthropometric, biochemical and sonographic characteristics,” International Journal of Clinical and Experimental Medicine, vol. 3, no. 3, pp. 202–210, 2010.
[61]
A. C. Gupta, A. K. Chaudhory, S. Sukriti et al., “Peroxisome proliferators-activated receptor γ2 Pro12Ala variant is associated with body mass index in non-alcoholic fatty liver disease patients,” Hepatology International, vol. 5, no. 1, pp. 575–580, 2011.
[62]
A. Esteghamati, A. Jamali, O. Khalilzadeh et al., “Metabolic syndrome is linked to a mild elevation in liver aminotransferases in diabetic patients with undetectable non-alcoholic fatty liver disease by ultrasound,” Diabetology and Metabolic Syndrome, vol. 2, no. 1, article 65, 2010.
[63]
Y. J. Park, J. H. Lim, E. R. Kwon et al., “Development and validation of a simple index system to predict nonalcoholic fatty liver disease,” The Korean journal of hepatology, vol. 17, no. 1, pp. 19–26, 2011.
[64]
I. Barchetta, F. Angelico, M. D. Ben et al., “Strong association between non alcoholic fatty liver disease (NAFLD) and low 25(OH) vitamin D levels in an adult population with normal serum liver enzymes,” BMC Medicine, vol. 9, article 85, 2011.
[65]
N. Alkhouri, T. A.-R. Tamimi, L. Yerian, R. Lopez, N. N. Zein, and A. E. Feldstein, “The inflamed liver and atherosclerosis: a Link between histologic severity of nonalcoholic fatty liver disease and increased cardiovascular risk,” Digestive Diseases and Sciences, vol. 55, no. 9, pp. 2644–2650, 2010.
[66]
J. Kaelsch, L. P. Bechmann, H. Kaelsch et al., “Evaluation of biomarkers of NAFLD in a cohort of morbidly obese patients,” Journal of Nutrition and Metabolism, vol. 2011, Article ID 369168, 7 pages, 2011.
[67]
F. Sentinelli, S. Romeo, C. Maglio et al., “Lack of effect of apolipoprotein C3 polymorphisms on indices of liver steatosis, lipid profile and insulin resistance in obese Southern Europeans,” Lipids in Health and Disease, vol. 10, article 93, 2011.
[68]
V. S. G. Ferreira, R. B. Pernambuco, E. P. Lopes et al., “Frequency and risk factors associated with non-alcoholic fatty liver disease in patients with type 2 diabetes mellitus,” Arquivos Brasileiros de Endocrinologia e Metabologia, vol. 54, no. 4, pp. 362–368, 2010.
[69]
C. A. Caserta, G. M. Pendino, A. Amante et al., “Cardiovascular risk factors, nonalcoholic fatty liver disease, and carotid artery intima-media thickness in an adolescent population in southern Italy,” American Journal of Epidemiology, vol. 171, no. 11, pp. 1195–1202, 2010.
[70]
S. Tan, L. P. Bechmann, S. Benson et al., “Apoptotic markers indicate nonalcoholic steatohepatitis in polycystic ovary syndrome,” Journal of Clinical Endocrinology and Metabolism, vol. 95, no. 1, pp. 343–348, 2010.
[71]
K. Yasui, Y. Sumida, Y. Mori et al., “Nonalcoholic steatohepatitis and increased risk of chronic kidney disease,” Metabolism: Clinical and Experimental, vol. 60, no. 5, pp. 735–739, 2011.
[72]
L. Sun and S.-Z. Lü, “Association between non-alcoholic fatty liver disease and coronary artery disease severity,” Chinese Medical Journal, vol. 124, no. 6, pp. 867–872, 2011.
[73]
M. Baba, K. Furuya, H. Bandou, K. Kasai, and K. Sadaoka, “Discrimination of individuals in a general population at high-risk for alcoholic and non-alcoholic fatty liver disease based on liver stiffness: a cross section study,” BMC Gastroenterology, vol. 11, article 70, 2011.
[74]
N. Tanaka, A. Horiuchi, T. Yokoyama et al., “Clinical characteristics of de novo nonalcoholic fatty liver disease following pancreaticoduodenectomy,” Journal of Gastroenterology, vol. 46, no. 6, pp. 758–768, 2011.
[75]
M. Akyildiz, F. Gunsar, D. Nart et al., “Macrophage migration inhibitory factor expression and MIF gene - 173 G/C polymorphism in nonalcoholic fatty liver disease,” European Journal of Gastroenterology and Hepatology, vol. 22, no. 2, pp. 192–198, 2010.
[76]
A. Verrijken, S. Francque, I. Mertens, M. Talloen, F. Peiffer, and L. Van Gaal, “Visceral adipose tissue and inflammation correlate with elevated liver tests in a cohort of overweight and obese patients,” International Journal of Obesity, vol. 34, no. 5, pp. 899–907, 2010.
[77]
M. Tsutsui, N. Tanaka, M. Kawakubo et al., “Serum fragmented cytokeratin 18 levels reflect the histologic activity score of nonalcoholic fatty liver disease more accurately than serum alanine aminotransferase levels,” Journal of Clinical Gastroenterology, vol. 44, no. 6, pp. 440–447, 2010.
[78]
Y. Yilmaz, O. Yonal, R. Kurt et al., “Serum levels of osteoprotegerin in the spectrum of nonalcoholic fatty liver disease,” Scandinavian Journal of Clinical and Laboratory Investigation, vol. 70, no. 8, pp. 541–546, 2010.
[79]
J. Raszeja-Wyszomirska, B. Szymanik, M. ？awniczak et al., “Validation of the BARD scoring system in Polish patients with nonalcoholic fatty liver disease (NAFLD),” BMC Gastroenterology, vol. 10, article 67, 2010.
[80]
E. M. Brunt, D. E. Kleiner, L. A. Wilson, P. Belt, and B. A. Neuschwander-Tetri, “Nonalcoholic fatty liver disease (NAFLD) activity score and the histopathologic diagnosis in NAFLD: Distinct clinicopathologic meanings,” Hepatology, vol. 53, no. 3, pp. 810–820, 2011.
[81]
Y. Sumida, Y. Yonei, K. Kanemasa et al., “Lower circulating levels of dehydroepiandrosterone, independent of insulin resistance, is an important determinant of severity of non-alcoholic steatohepatitis in Japanese patients,” Hepatology Research, vol. 40, no. 9, pp. 901–910, 2010.
[82]
H. Park, A. Ishigami, T. Shima et al., “Hepatic senescence marker protein-30 is involved in the progression of nonalcoholic fatty liver disease,” Journal of Gastroenterology, vol. 45, no. 4, pp. 426–434, 2010.
[83]
C. P. M. S. Oliveira, J. T. Stefano, A. M. Cavaleiro et al., “Association of polymorphisms of glutamate-cystein ligase and microsomal triglyceride transfer protein genes in non-alcoholic fatty liver disease,” Journal of Gastroenterology and Hepatology, vol. 25, no. 2, pp. 357–361, 2010.
